Welcome to our dedicated page for Sonnet Biotherapeutc Hldng news (Ticker: SONN), a resource for investors and traders seeking the latest updates and insights on Sonnet Biotherapeutc Hldng stock.
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) is a clinical-stage biotechnology innovator developing targeted immunotherapies through its proprietary FHAB platform. This page serves as the definitive source for verified company announcements, including clinical trial updates, regulatory milestones, and strategic developments in immuno-oncology.
Investors and researchers will find timely updates on SONN's pipeline progress, including its lead candidates targeting cancer and immune-mediated conditions. Our curated news collection features press releases about FHAB technology advancements, partnership announcements, and financial disclosures – all essential for tracking this innovative biotech's trajectory.
The repository systematically organizes updates across key categories: new patent filings, preclinical data publications, Phase 1 trial results, and executive team developments. Each entry maintains strict editorial standards to ensure compliance with financial reporting regulations.
For those monitoring advancements in bispecific antibody therapies and tumor microenvironment modulation, this resource offers structured access to SONN's scientific and corporate developments. Bookmark this page for efficient tracking of how the company's platform-based approach translates to clinical progress and strategic positioning within the competitive oncology landscape.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN), a clinical-stage biopharmaceutical firm, announced a webcast on April 18, 2023, at 5:00 pm ET to present data from its SB101 study with SON-1010 involving oncology patients (NCT05352750). Presenters include Richard Kenney, M.D. and Pankaj Mohan, Ph.D.. The webcast will offer a detailed overview of the clinical trial and will be available for later access on the company's website. Also, a poster presentation titled Clinical development of a novel form of interleukin-12 will occur during the AACR 2023 Annual Meeting on April 18, from 1:30 pm to 5:00 pm ET. Sonnet's FHB technology aims to enhance the efficacy of immunotherapeutic drugs by targeting tumor tissues effectively, which is essential for its ongoing clinical applications.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) announced it will present data from the SB101 multiple-dose clinical trial of SON-1010 (IL12-FHAB) at the AACR Annual Meeting 2023 in Orlando, Florida, from April 14-19. The presentation, titled "Clinical development of a novel form of interleukin-12 with extended pharmacokinetics," is scheduled for April 18, 2023, from 1:30 PM to 5:00 PM. SON-1010 is designed for treating adult patients with advanced solid tumors and utilizes FHAB technology for improved targeting of tumor and lymphatic tissues. This marks a significant step in Sonnet's commitment to advancing oncology treatments.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced its financial results for Q1 FY 2023, highlighting significant developments in its clinical trials and collaborations. The company presented positive early clinical data for SON-1010, a promising IL-12 candidate, and completed IND-enabling toxicology studies for SON-1210. A collaboration with Janssen Biotech is set to evaluate three pipeline compounds. Financially, Sonnet raised $15 million from a public offering, although it reported a net loss of $5.54 million for the quarter, with cash on hand totaling $1.7 million. The company plans to reduce operating expenses by approximately 30% to extend its cash runway.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) announced the pricing of an underwritten public offering of 13,888,888 shares of common stock at a price of $1.08 per share, expected to generate approximately $15 million in gross proceeds before expenses.
This offering includes investor warrants enabling the purchase of up to 27,777,776 additional shares. Net proceeds will be used for further R&D, clinical trials, and general corporate purposes. The offering is set to close on February 10, 2023, pending customary conditions.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced the successful completion of two IND-enabling toxicology studies for SON-1210, its lead bifunctional therapeutic candidate. The studies showed no serious adverse events, and SON-1210 was well-tolerated at doses 50 times higher than expected human levels. Observations included a controlled rise in interferon gamma (IFNg) without cytokine release syndrome or off-target toxicity. The results pave the way for regulatory filings in the first half of 2023, aimed at initiating human trials, particularly for targeting cancers by stimulating an immune response.
Sonnet BioTherapeutics (NASDAQ:SONN) announced dosing of 24 healthy volunteers in a Phase 1 clinical trial for SON-1010, aimed at assessing safety and pharmacokinetics (PK). SON-1010 shows a remarkable half-life of approximately 112 hours, significantly longer than the 12 hours of rhIL-12. Early results indicate successful induction of interferon gamma (IFNg) with minimal adverse events, allowing for potential dose escalation. The findings support the effectiveness of the FHAB platform in enhancing drug delivery to tumors, suggesting promising implications for future cancer therapies and potential market opportunities.
Sonnet BioTherapeutics (NASDAQ: SONN) announced a clinical collaboration with Roche to evaluate its lead product, SON-1010, alongside atezolizumab in a study targeting platinum-resistant ovarian cancer. Scheduled to begin in Q2 2023, the Phase 1b/2a trial (SB221) will assess safety and efficacy. SON-1010 is designed to enhance immune response in the tumor microenvironment, potentially improving treatment options for patients with limited alternatives. This marks Sonnet's first combination study, highlighting its importance for the company's growth strategy.
Sonnet BioTherapeutics Holdings (NASDAQ:SONN) reported its fiscal year 2022 results, highlighting significant development milestones. The company initiated two Phase 1 trials for SON-1010, showing promising safety data, and commenced a Phase 1b/2a trial for SON-080, with results anticipated in H1 2023. Sonnet plans a 30% operational expense reduction starting Q2 2023, focusing on enhancing pipeline efficiency and leveraging cost-effective R&D locations. After raising $6.5 million in common stock sales, Sonnet's cash on hand was $3.1 million as of September 30, 2022. Research and development expenses rose to $21.4 million, mainly due to advancing clinical trials.
Sonnet BioTherapeutics announced encouraging interim results from Phase 1 trials of SON-1010, a novel immunotherapeutic targeting advanced solid tumors. A total of 36 subjects have been dosed, with an ongoing dose escalation approved by safety review committees. Key findings include controlled induction of IFNγ and no instances of cytokine release syndrome. Notably, all but one patient remain in the study, and one has displayed tumor improvement after 6 months. The safety profile is favorable, with mild to moderate adverse events, suggesting SON-1010's potential in enhancing immunotherapy.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced a webcast on November 2, 2022, at 8:30 am ET to share initial clinical data from two studies involving SON-1010. The SB101 trial assesses the safety of SON-1010 in cancer patients, focusing on establishing the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Concurrently, the SB102 trial evaluates SON-1010 doses in healthy volunteers. Both studies aim to understand safety, pharmacokinetics, and immunogenicity, setting the stage for future immunotherapy combinations.
